Oct. 20 at 3:10 PM
$CMND has announced the publication of a patent application by the USPTO for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders
https://biotuesdays.com/2025/10/20/uspto-publishes-patent-application-for-clearminds-meai-for-binge-behavior-disorders/